RECRUITING

Adaptive Optics Imaging of Outer Retinal Diseases

Description

The objective of the study is to collect adaptive optics (AO) retinal images from human subjects with outer retinal diseases (diseases of the outer retina including photoreceptor, retinal pigment epithelium (RPE), basement membrane or choroidal pathologies) to develop new diagnostic methods, biomarkers, and clinical endpoints.

Conditions

Retinal DegenerationAge-Related Macular DegenerationRetinitis PigmentosaHydroxychloroquine RetinopathyUsher SyndromesLate-Onset Retinal DegenerationCone DystrophyCone Rod DystrophyRod Cone DystrophyRod Dystrophy
Talk to us

Related Conditions:

Retinal DegenerationAge-Related Macular DegenerationRetinitis PigmentosaHydroxychloroquine RetinopathyUsher SyndromesLate-Onset Retinal DegenerationCone DystrophyCone Rod DystrophyRod Cone DystrophyRod Dystrophy

Study Overview

On this page

Study Details

Study overview

The objective of the study is to collect adaptive optics (AO) retinal images from human subjects with outer retinal diseases (diseases of the outer retina including photoreceptor, retinal pigment epithelium (RPE), basement membrane or choroidal pathologies) to develop new diagnostic methods, biomarkers, and clinical endpoints.

Adaptive Optics Imaging of Outer Retinal Diseases

Adaptive Optics Imaging of Outer Retinal Diseases

Condition
Retinal Degeneration
Intervention / Treatment

-

Contacts and Locations

Bethesda

NIH Clinical Center, Bethesda, Maryland, United States, 20810

Silver Spring

Food and Drug Administration, Silver Spring, Maryland, United States, 20993

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • 1. Are 21 years of age or older,
  • 2. Have the ability to cooperate with instructions during adaptive optics imaging (similar to instructions given during a clinical eye exam),
  • 3. Have the ability to understand and sign an informed consent. (Non-English speaking participants will not be enrolled into the study), and
  • 4. Have been diagnosed with outer retinal disease or condition (Cohort 2).
  • 1. Have a condition which prevents adequate images from being obtained (e.g. unstable fixation or media opacity),
  • 2. Have visual correction outside of the range +4 diopters (D) to -8 D,
  • 3. Have a history of adverse reaction to mydriatic drops,
  • 4. Have a predisposition to (i.e., narrow iridocorneal angle) or any history of acute angle closure glaucoma (AACG), or
  • 5. Are working under the direct supervision of Drs. Hammer, Cukras and Liu, or any of the NIH/NEI AIs.

Ages Eligible for Study

21 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Food and Drug Administration (FDA),

Daniel X Hammer, Ph.D., PRINCIPAL_INVESTIGATOR, Food and Drug Administration (FDA)

Study Record Dates

2024-04-25